Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF)
$ 43.78 -3.2505 (-6.91%) Market Cap: 73.00 Bil Enterprise Value: 73.11 Bil PE Ratio: 27.66 PB Ratio: 6.65 GF Score: 81/100

Chugai Pharmaceutical Co Ltd Antibody Engineering Technologies Information Meeting Transcript

Dec 09, 2019 / NTS GMT
Release Date Price: $21.35
Junichi Nezu
Chugai Pharmaceutical Co., Ltd. - General Manager of Research Division

Thank you for attending this meeting today. My name is Nezu, the General Manager of Research Division of Chugai. This is an information meeting on antibody engineering technologies. But before Igawa talks about it, I'd like to briefly explain Chugai's strategy for drug discovery research and the positioning of antibody engineering technologies in the overall strategy.

Please be aware of important reminders. Chugai developed a new midterm business [plan] this year, which includes 5 strategies. Our research division is involved in the strategy 1, value creation, aiming at realizing innovative drug discovery to cure and manage diseases. For that purpose, we developed a basic policy of drug discovery strategy since I became a general manager of that division, and we promote various strategies based on it. The basic policy is the fusion of biology and technology generates innovations in drug discovery. The drug discovery innovation is to create innovative and medically valuable drugs, and that is what we are aiming at in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot